EP3272746B1 - Sels de dérivé de quinazoline et procédé de préparation associé - Google Patents

Sels de dérivé de quinazoline et procédé de préparation associé Download PDF

Info

Publication number
EP3272746B1
EP3272746B1 EP16767717.8A EP16767717A EP3272746B1 EP 3272746 B1 EP3272746 B1 EP 3272746B1 EP 16767717 A EP16767717 A EP 16767717A EP 3272746 B1 EP3272746 B1 EP 3272746B1
Authority
EP
European Patent Office
Prior art keywords
compound
formula
maleate
maleic acid
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP16767717.8A
Other languages
German (de)
English (en)
Other versions
EP3272746A1 (fr
EP3272746A4 (fr
Inventor
Xiquan Zhang
Song TANG
Weiwei FENG
Xin Tian
Zhilin Chen
Hongmei Gu
Hongjiang Xu
Fei Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centaurus Biopharma Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Original Assignee
Centaurus Biopharma Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centaurus Biopharma Co Ltd, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd filed Critical Centaurus Biopharma Co Ltd
Publication of EP3272746A1 publication Critical patent/EP3272746A1/fr
Publication of EP3272746A4 publication Critical patent/EP3272746A4/fr
Application granted granted Critical
Publication of EP3272746B1 publication Critical patent/EP3272746B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present application relates to the field of pharmaceutical chemistry, and more particularly, to a salt of a quinazoline derivative, a method for preparing the same and a medical use thereof.
  • EGFR Epidermal Growth Factor Receptor
  • EGFR signaling pathway plays an important role in the physiological processes of cells, such as growth, proliferation, differentiation and the like.
  • the functional deficiency of protein tyrosine kinases, such as EGFR, etc., or the abnormality in the activity or cellular localization of key factors in the related signaling pathway, may all cause occurrence of tumors, diabetes, immune deficiencies and cardiovascular diseases.
  • N 6 -(1-acryloylazacyclohexan-4-yl)-N 4 -(3-chloro-4-fluorophenyl)-7-methoxy quinazoline-4,6-diamine has a structure represented by Formula I
  • the compound of Formula I is a selective epidermal growth factor receptor inhibitor. It can competitively bind to the phosphorylation site of tyrosine kinase at an intracellular domain to block an interaction between the phosphorylation site and ATP, and thereby inhibit the tyrosine phosphorylation and a series of downstream signal transduction, and then inhibit the growth of tumor cells.
  • the compound of Formula I therefore can be used to treat various malignant tumors, such as non-small cell lung cancer, breast cancer and the like. See Chinese Patent Application No. 2013104528854 .
  • the present application provides a maleate of a compound of Formula I, wherein a molar ratio of maleic acid to the compound of Formula I depends on the amount of maleic acid used in the preparation of said salt.
  • the molar ratio of the compound of Formula I to maleic acid in the maleate may be in a range of 1:0.5-4.
  • the present application provides a method for preparing a maleate of a compound of Formula I, comprising: (1) preparing a solution of the compound of Formula I; (2) contacting the solution of the compound of Formula I obtained from step (1) with maleic acid; and (3) spray-drying a reaction mixture obtained from step (2) to afford the maleate of the compound of Formula I.
  • the present application provides a pharmaceutical composition, comprising a maleate of a compound of Formula I and a pharmaceutically acceptable carrier, excipient, diluent and/or vehicle.
  • the present application provides a maleate of a compound of Formula I or a pharmaceutical composition thereof for use in the treatment of a tumor.
  • the present application provides a maleate of a compound of Formula I, wherein a molar ratio of maleic acid to the compound of Formula I depends on the amount of maleic acid used in the preparation of said salt.
  • the molar ratio of the compound of Formula I to maleic acid in the maleate may be in a range of 1:0.5-4.
  • the molar ratio of the compound of Formula I to maleic acid in the maleate is 1:1. In still other embodiments of the present application, the molar ratio of the compound of Formula I to maleic acid in the maleate is 1:2.
  • the present application provides a preparation method of a maleate of a compound of Formula I, comprising (1) preparing a solution of a compound of Formula I; (2) mixing the solution of the compound of Formula I obtained from step (1) with maleic acid; and (3) spray-drying a reaction mixture obtained from step (2) to afford the maleate of the compound of Formula I.
  • a molar ratio of the amount of the compound of Formula I to that of maleic acid used in the preparation method is in a range of 1:1-20, preferably 1:1-15, and most preferably 1:1-10.
  • the compound of Formula I may be dissolved in an organic solvent to prepare a solution of the compound of Formula I.
  • the organic solvent includes all organic solvents capable of dissolving the compound of Formula I, such as DMF.
  • the solution of the compound of Formula I obtained from step (1) may be mixed with maleic acid or a solution of maleic acid, and if necessary, the resulting reaction mixture may be heated to a suitable temperature, for example, 60 °C to 100 °C, preferably 80 °C.
  • the solution of maleic acid is an organic solution of maleic acid obtained by mixing maleic acid with an organic solvent.
  • the organic solvent is, for example, DMF.
  • a solvent miscible with the organic solvents used in step (1) and/or step (2), such as water, may be added prior to the spray-drying.
  • the present application provides a pharmaceutical composition
  • a pharmaceutical composition comprising a maleate of a compound of Formula I and a pharmaceutically acceptable carrier, excipient, diluent and/or vehicle.
  • pharmaceutical composition refers to a formulation produced by a compound of the present application and a carrier, excipient, diluent and/or vehicle that is generally accepted in the medicine field for the delivery of a bioactive compound to an organism (e.g., human).
  • the purpose of the pharmaceutical composition is to facilitate the administration of the compound of the present application to the organism.
  • pharmaceutically acceptable carrier refers to those carriers and diluents that do not cause significant stimulation to an organism, and will not impair the bioactivity and properties of an active compound.
  • “Pharmaceutically acceptable excipient and/or vehicle” refers to an inert substance that is administered together with an active ingredient and is beneficial to the delivery of the active ingredient to an organism.
  • “Pharmaceutically acceptable carrier, excipient, diluent and/or vehicle” include, but are not limited to, any carriers, excipients, vehicles, glidants, sweetening agents, diluents, preservatives, dyes/colorants, flavoring agents, surfactants, wetting agents, dispersants, disintegrants, suspending agents, stabilizers, isotonic agents, solvents, or emulsifier, and the like, which can be used in human or livestock.
  • Non-limiting examples of an excipient include calcium carbonate, calcium phosphate, various sugars and starches, cellulose derivatives, gelatins, vegetable oils, polyethylene glycols, and the like.
  • the maleate of the compound of Formula I of the present application may be administered in its pure form or in the form of an appropriate pharmaceutical composition.
  • the pharmaceutical composition of the present application may be prepared by combining the maleate of the compound of Formula I of the present application with an appropriate pharmaceutically acceptable carrier, diluent or excipient, and may be formulated into solid, semi-solid, liquid or gaseous formulations, such as tablets, pills, capsules, powders, granules, ointments, emulsions, suspensions, solutions, suppositories, injections, inhalants, gels, microspheres, aerosols, and the like.
  • Typical administration routes of the maleate of the compound of Formula I of the present application or the pharmaceutical composition thereof include, but are not limited to, oral, rectal, transmucosal, enteral administration, or local, transdermal, inhalation, parenteral, sublingual intravaginal, intranasal, intraocular, intraperitoneal, intramuscular, subcutaneous, and intravenous administration.
  • the preferred administration route is the oral administration.
  • the pharmaceutical composition of the present application may be prepared by using a method known to a person skilled in the art, such as a conventional mixing method, dissolution method, granulation method, dragee manufacture method, grinding method, emulsification method, freeze-drying method, and the like.
  • the pharmaceutical composition of the present application is in oral form.
  • the pharmaceutical composition may be formulated by mixing the active compound with a pharmaceutically acceptable carrier, excipient, diluent and/or vehicle well-known in the art. These carriers, excipients, diluents and/or vehicles enable the pharmaceutical composition of the present application to be formulated into tablets, pills, lozenges, dragees, capsules, liquids, gels, syrups, suspensions, and the like, for oral administration to a patient.
  • a solid oral composition may be prepared by a conventional mixing, filling or tabletting method.
  • a dosage of the maleate of the compound of Formula I is preferably 0.01-200mg/kg body weight per day.
  • the present application provides a maleate of a compound of Formula I or a pharmaceutical composition thereof for use in the treatment of a tumor.
  • the tumor includes, but is not limited to, non-small cell lung cancer and breast cancer.
  • Step 3 N-(3-chloro-4-fluorophenyl)-N-(3,4-dimethoxybenzyl)-7-fluoro-6-nitroquinazoline -4-amine
  • Step 4 N-(3-chloro-4-fluorophenyl)-N-(3,4-dimethoxybenzyl)-7-methoxy-6-nitroquinazoline -4-amine
  • Step 5 N 4 -(3-chloro-4-fluorophenyl)-N 4 -(3,4-dimethoxybenzyl)-7-methoxyquinazoline-4,6-diamine
  • N-(3-chloro-4-fluorophenyl)-N-(3,4-dimethoxybenzyl)-7-methoxy-6-nitroquinazoline-4-amine (2.35 g, 4.7 mmol) and Raney nickel (about 0.5 g) were added to tetrahydrofuran (100 mL). The atmosphere was replaced with hydrogen gas, and the reaction mixture was stirred overnight at room temperature under a hydrogen atmosphere (1 atm). The mixture was filtered, and the filtrate was concentrated in vacuo to afford the title compound (2 g, 90%).
  • Step 6 tert-butyl 4- ⁇ 4-[(3-chloro-4-fluorophenyl)(3,4-dimethoxybenzyl)amino]-7-methoxyquinazolin-6-yl ⁇ amino ⁇ piperidine-1-carboxylate
  • Step 7 N 6 -(piperidin-4-yl)-N 4 -(3-chloro-4-fluorophenyl)-7-methoxyquinazoline-4,6-diamine
  • Step 8 N 6 -(1-acryloylpiperidin-4-yl)-N 4 -(3-chloro-4-fluorophenyl)-7-methoxyquinazoline-4,6-diamine
  • citrate, oxalate and acetate of the compound of Formula I were respectively prepared in the same manner as Example 2.
  • Mass spectrometry conditions ion source: ESI ionization source, scanning in SIM mode, 250 °C of curved desolventizer (CDL) temperature, 200 °C of heating block temperature; 25V of CDL voltage; +1.60 kV of detection voltage; 1.5 L/min of atomization gas flow rate; 2.0 L/min of dry gas flow rate.
  • CDL curved desolventizer
  • EGFR, EGFR (T790M, L858R), and HER2 kinase were expressed and purified through an insect cell expression system, or purchased from commercially available products.
  • a platform for testing the kinase activities of EGFR, EGFR (T790M, L858R) and HER2 was established based on Homogeneous Time-Resolved Fluorescence (HTRF) method provided by Cisbio Bioassays, and the activity of the compound was determined with the platform.
  • the compound was diluted at a 3-fold gradient with 100% DMSO, starting from 100 nM (EGFR and HER2) and 1 ⁇ M (EGFR-T790M/L858R), respectively.
  • reaction buffer 50 mM 4-hydroxyethylpiperazineethanesulfonic acid (HEPES) (pH 7.0), 0.02% NaN 3 , 0.01% bovine serum albumin (BSA), 0.1 mM Sodium Orthovanadate, 5 mM MgCl 2 , 50 nM SEB (Cisbio, Cat No.: 61SEBALB), 1 mM DTT.
  • HEPES 4-hydroxyethylpiperazineethanesulfonic acid
  • BSA bovine serum albumin
  • 0.1 mM Sodium Orthovanadate 5 mM MgCl 2
  • 50 nM SEB Cisbio, Cat No.: 61SEBALB
  • 1 mM DTT 1 mM DTT
  • NCI-H1975, a human non-small cell lung cancer cell, and BT474, a human breast cancer cell line were cultured in RPIM-1640 or DMEM culture medium supplemented with 10% fetal bovine serum (FBS) in a cell incubator (37 °C, 5% CO 2 ).
  • FBS fetal bovine serum
  • culture plates were pre-coated with 0.6% medium, and the cells were resuspended with 0.3% low-melting-point agarose, and then seeded in a 96-well plate at a density of 10,000 cells per well (100 ⁇ L). The compound was diluted at a 3-fold gradient, starting from 10 mM.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (9)

  1. Maléate d'un composé de formule I,
    Figure imgb0014
  2. Maléate du composé de formule I selon la revendication 1, dans lequel un rapport molaire du composé de formule I à l'acide maléique est de 1:0,5-4.
  3. Maléate du composé de formule I selon la revendication 2, dans lequel le rapport molaire du composé de formule I à l'acide maléique est de 1:1 ou 1:2.
  4. Procédé de préparation du maléate du composé de formule I selon l'une quelconque des revendications 1 à 3, comprenant, (1) la préparation d'une solution du composé de formule I ; (2) le mélange de la solution du composé de formule I obtenue à l'étape (1) avec de l'acide maléique ; et (3) le séchage par pulvérisation d'un mélange réactionnel obtenu à l'étape (2) pour obtenir le maléate du composé de formule I.
  5. Procédé selon la revendication 4, dans lequel un rapport molaire de la quantité du composé de formule I à celle de l'acide maléique est de 1:1 à 20, de préférence de 1:1 à 15, et plus préférablement de 1:1 à 10.
  6. Procédé selon la revendication 4 ou 5, dans lequel, dans l'étape (1), le composé de formule I est dissous dans un solvant organique pour préparer la solution du composé de formule I, et le solvant organique est de préférence DMF.
  7. Procédé selon la revendication 6, dans lequel un solvant miscible avec le solvant organique est ajouté avant le séchage par pulvérisation, et le solvant miscible avec le solvant organique est de préférence de l'eau.
  8. Composition pharmaceutique comprenant le maléate du composé de formule I selon l'une quelconque des revendications 1 à 3, et un support, excipient, diluant et/ou véhicule pharmaceutiquement acceptable.
  9. Maléate du composé de formule I selon l'une quelconque des revendications 1 à 3 ou de la composition pharmaceutique selon la revendication 8, destiné à être utilisé dans le traitement d'une tumeur.
EP16767717.8A 2015-03-20 2016-03-18 Sels de dérivé de quinazoline et procédé de préparation associé Active EP3272746B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510125962 2015-03-20
PCT/CN2016/076693 WO2016150340A1 (fr) 2015-03-20 2016-03-18 Sels de dérivé de quinazoline et procédé de préparation associé

Publications (3)

Publication Number Publication Date
EP3272746A1 EP3272746A1 (fr) 2018-01-24
EP3272746A4 EP3272746A4 (fr) 2018-11-07
EP3272746B1 true EP3272746B1 (fr) 2019-12-25

Family

ID=56977000

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16767717.8A Active EP3272746B1 (fr) 2015-03-20 2016-03-18 Sels de dérivé de quinazoline et procédé de préparation associé

Country Status (8)

Country Link
US (1) US10231973B2 (fr)
EP (1) EP3272746B1 (fr)
JP (1) JP6704422B2 (fr)
CN (1) CN107406430B (fr)
ES (1) ES2775614T3 (fr)
HK (1) HK1244278B (fr)
RU (1) RU2720810C2 (fr)
WO (1) WO2016150340A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113149960A (zh) * 2016-08-25 2021-07-23 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐的晶体
CN108069946B (zh) * 2016-11-08 2020-06-05 威尚（上海）生物医药有限公司 具有穿过血脑屏障能力的取代的喹唑啉化合物
EP3988553A4 (fr) * 2019-06-19 2023-06-14 Chengdu Jinrui Foundation Biotech Co., Ltd. Forme cristalline et sel d'un composé de quinazoline, et procédé de préparation associé
WO2021043200A1 (fr) * 2019-09-04 2021-03-11 正大天晴药业集团股份有限公司 Procédé de préparation d'un dérivé de quinazoline et cristallisation de ce dernier
CN110627731A (zh) * 2019-10-09 2019-12-31 贵州大学 一类4-氨基喹唑啉接丙烯酰胺类化合物及其制备方法和应用
CN114845723B (zh) * 2019-11-01 2024-09-13 正大天晴药业集团股份有限公司 包含喹唑啉衍生物或其盐的药物组合物
WO2021083347A1 (fr) * 2019-11-01 2021-05-06 正大天晴药业集团股份有限公司 Utilisation d'un dérivé de quinazoline ou d'un sel de celui-ci ou d'une composition pharmaceutique associée
CN114761010B (zh) * 2019-11-25 2024-04-16 正大天晴药业集团股份有限公司 喹唑啉衍生物或其盐的联用药物组合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
HUP0104211A3 (en) 1998-11-19 2003-01-28 Warner Lambert Co N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases and pharmaceutical composition containing it
DE10063435A1 (de) * 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
UA83252C2 (uk) 2003-09-19 2008-06-25 Астразенека Аб Похідні хіназоліну, спосіб їх одержання (варіанти), фармацевтична композиція на їх основі, проміжна сполука
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
WO2007055513A1 (fr) 2005-11-08 2007-05-18 Hanmi Pharm. Co., Ltd. Dérivés de quinazoline en tant qu'inhibiteurs de transduction de signal et méthode de synthèse desdits dérivés
CN101003514A (zh) 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
WO2008002039A1 (fr) 2006-06-28 2008-01-03 Hanmi Pharm. Co., Ltd. Dérivés de quinazoline destinés à inhiber le développement de cellules cancéreuses
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
KR20100087185A (ko) 2007-10-29 2010-08-03 낫코 파마 리미티드 항암제로서의 신규한 4-(테트라졸-5-일)-퀴나졸린 유도체
ES2575710T3 (es) 2011-09-22 2016-06-30 Pfizer Inc Derivados de pirrolopirimidina y purina
KR101272613B1 (ko) 2011-10-05 2013-06-10 한미사이언스 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체
CN104513229A (zh) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
CN103948689A (zh) * 2014-04-15 2014-07-30 西北农林科技大学 用于治疗非小细胞肺癌的药物组合物及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
JP2018508583A (ja) 2018-03-29
EP3272746A1 (fr) 2018-01-24
RU2017132330A (ru) 2019-04-22
RU2017132330A3 (fr) 2019-07-24
CN107406430B (zh) 2019-04-26
US10231973B2 (en) 2019-03-19
US20180085369A1 (en) 2018-03-29
CN107406430A (zh) 2017-11-28
JP6704422B2 (ja) 2020-06-03
WO2016150340A1 (fr) 2016-09-29
EP3272746A4 (fr) 2018-11-07
ES2775614T3 (es) 2020-07-27
RU2720810C2 (ru) 2020-05-13
HK1244278B (zh) 2020-04-17

Similar Documents

Publication Publication Date Title
EP3272746B1 (fr) Sels de dérivé de quinazoline et procédé de préparation associé
JP6141568B1 (ja) 新規なピラゾロ［３，４−ｄ］ピリミジン化合物又はその塩
EP3381918A1 (fr) Utilisation du composé 7-(thiazol-5-yl)pyrrolopyrimidine comme agoniste de tlr7
EP3412671B1 (fr) Sel de maléate d'agoniste du tlr7, formes cristallines c, d et e de celui-ci, procédés de préparation et utilisations du sel de maléate et de ses formes cristallines
US20100273808A1 (en) Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders
EP3412674B1 (fr) Sel de trifluoroacétate d'un agoniste de tlr7, sa forme cristalline b, ses procédés de préparation et ses utilisations
CN102482277A (zh) 表皮生长因子受体抑制剂及治疗障碍的方法
EP3459952B1 (fr) Dérivé pyrimidine, procédé de préparation et utilisation associée en médecine
CN116528864A (zh) 杂芳基甲酰胺化合物
CN108350006A (zh) 氘修饰的Brigatinib衍生物、含有该化合物的药物组合物及其用途
CN113717245A (zh) 含有2,8,9-三取代-9h-嘌呤结构片段的egfr降解剂及其盐和应用
WO2019223777A1 (fr) Composé pyrrolopyrimidine contenant une substitution arylamine, son procédé de préparation et son application
AU2017326029B2 (en) Deuterated 3-(4,5-substituted pyrimidinamine) phenyl derivatives and applications thereof
WO2018159613A1 (fr) Activateur d'effet antitumoral utilisant un composé pyrazolo[3,4-d]pyrimidine
US20150133460A1 (en) Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders
EP3632912B1 (fr) Inhibiteurs de protéine kinase
JP2020180140A (ja) ジヒドロクロメン誘導体
CN112961081B (zh) 一种联苯甲酰胺脲类化合物及其制备方法和应用
AU2014361633B2 (en) Quinazoline derivative

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170901

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20181008

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 401/12 20060101ALI20181001BHEP

Ipc: A61K 31/517 20060101ALI20181001BHEP

Ipc: A61K 31/4427 20060101ALI20181001BHEP

Ipc: A61K 31/5377 20060101ALI20181001BHEP

Ipc: C07D 405/14 20060101ALI20181001BHEP

Ipc: C07D 211/40 20060101ALI20181001BHEP

Ipc: A61P 35/00 20060101ALI20181001BHEP

Ipc: C07D 239/94 20060101ALI20181001BHEP

Ipc: C07D 403/12 20060101AFI20181001BHEP

Ipc: A61K 45/06 20060101ALI20181001BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190711

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD.

Owner name: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

Owner name: CENTAURUS BIOPHARMA CO., LTD.

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016026915

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1216984

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: TR-IP CONSULTING LLC, CH

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191225

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200326

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191225

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200325

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200325

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191225

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191225

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191225

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2775614

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20200727

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191225

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191225

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200520

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200425

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191225

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191225

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016026915

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191225

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191225

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1216984

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191225

26N No opposition filed

Effective date: 20200928

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191225

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191225

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230224

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20230223

Year of fee payment: 8

Ref country code: FR

Payment date: 20230221

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230317

Year of fee payment: 8

Ref country code: SE

Payment date: 20230227

Year of fee payment: 8

Ref country code: IT

Payment date: 20230228

Year of fee payment: 8

Ref country code: GB

Payment date: 20230216

Year of fee payment: 8

Ref country code: DE

Payment date: 20230214

Year of fee payment: 8

Ref country code: BE

Payment date: 20230216

Year of fee payment: 8

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230601

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20230405

Year of fee payment: 8

Ref country code: CH

Payment date: 20230401

Year of fee payment: 8

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG